141 – 150 of 330
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
PBX3 is a putative biomarker of aggressive prostate cancer
(
- Contribution to journal › Article
-
Mark
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer : A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice
(
- Contribution to journal › Article
-
Mark
The Proteome of Primary Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
(
- Contribution to journal › Article
- 2015
-
Mark
Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.
(
- Contribution to journal › Article
-
Mark
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
2015) In European Urology(
- Contribution to journal › Article
-
Mark
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(7 Suppl). p.288-288(
- Contribution to journal › Published meeting abstract
-
Mark
Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(15 Suppl). p.5044-5044(
- Contribution to journal › Published meeting abstract